Suchergebnisse - "Shah, Rashmi R"

PubPharm (7)

1

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology

enthalten in: Drug safety | 2019

von Shah, R. | Shah, D.

2

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome : Could Hypomagnesaemia Be the Trigger?

enthalten in: Drug safety | 2017

von Shah, R.

3

Effect of tyrosine kinase inhibitors on wound healing and tissue repair : implications for surgery in cancer patients

enthalten in: Drug safety | 2014

von Shah, D. | Dholakia, S. | Shah, R.

4

A fresh perspective on comparing the FDA and the CHMP/EMA : approval of antineoplastic tyrosine kinase inhibitors

enthalten in: British journal of clinical pharmacology | 2013

von Shah, R. | Roberts, S. | Shah, D.

5

Hepatotoxicity of tyrosine kinase inhibitors : clinical and regulatory perspectives

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

6

Tyrosine kinase inhibitors : their on-target toxicities as potential indicators of efficacy

enthalten in: Drug safety | 2013

von Shah, D. | Shah, R. | Morganroth, J.

7

Cardiovascular safety of tyrosine kinase inhibitors : with a special focus on cardiac repolarisation (QT interval)

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

1
[1]